HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Absent Mandatory Listing, US FDA Acknowledges Its Supplement Directory Isn’t Comprehensive

Executive Summary

Two weeks after Commissioner Califf notes he supports mandatory listing of supplements and two months after previous session of Congress ended without imposing requirement, agency is doing what it can to publish information about ingredients in supplements sold in the country.

You may also be interested in...



House Members Take STAND On Tianeptine As ‘Unregulated Drug’ In Supplements

Reps. Panetta and Pfluger introduce Scheduling Tianeptine and Analogues Now to Defend Against Emerging Opioids Act to make tianeptine a schedule III controlled substance a day after FDA posts latest alert to warn consumers against using products containing ingredient known as “gas station heroin.”

Tianeptine Rings Latest Unapproved Drug Alarm, Followed By Echo About Lack Of FDA Regulation

Tianeptine isn’t approved as drug in US nor allowed for use as dietary ingredient or food additive. FDA has warned multiple firms selling tianeptine-containing products and federal prosecutors recently announced guilty plea from man who sold the drug to consumers.

Good ‘Fit’ For Regulation Shifting US FDA's ODSP Into Larger Food Safety Program – Director

ODSP Director Cara Welch spoke about food programs structure and other supplement industry regulatory news days before first day on the job for agency’s first deputy commissioner for human foods, a post added in the human foods reorganization plan.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel